ArticleFrontiers in immunology2026
Case Report: Multimodal management of duodenal metastasis from hepatocellular carcinoma complicated by intractable hemorrhage.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commentary: Case Report: Multimodal management of duodenal metastasis from hepatocellular carcinoma complicated by intractable hemorrhage.Frontiers in immunology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma with duodenal involvement is a rare clinical entity with limited treatment options. Here, we report a case of advanced hepatocellular carcinoma and portal vein tumor thrombus with metastatic involvement of the duodenum that resulted in a recurrent gastrointestinal hemorrhage in a 64-year-old male. Following comprehensive diagnostic evaluation, including endoscopy, imaging, and histopathological biopsy, the patient was managed with a multimodal approach that consisted of interventional embolization for hemostasis, followed by systemic immunotherapy with tislelizumab. This therapeutic strategy successfully achieved hemorrhage control and resulted in significant radiological regression of both the duodenal metastatic lesion and the primary hepatic tumor. This case highlights the importance of a systematic diagnostic approach and suggests that immunotherapy-based regimens may hold promise in the management of advanced hepatocellular carcinoma with uncommon metastatic manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.